Best Biopharmaceuticals Companies in United States

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Operator of a clinical-stage company intended to treat multi-drug resistant pathogenic bacteria. The company provides services by using clinical and therapeutic technology that matches phages to patient-specific bacterial infections, enabling medical researchers to develop drugs that can detect and eliminate multi-drug resistant bacteria.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Developer of novel small-molecule antibiotics intended to focus on the treatment of resistant infections. The company develops treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections and is focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications, enabling clients to get safe and differentiated antibiotics for acute care.

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.

Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.

Developer of novel therapeutic and diagnostic products. The company focuses on developing novel therapeutic and diagnostic products for the treatment of pancreatic, colon, lung, prostate and various other cancers.

Developer of therapeutic drugs intended to facilitate early detection and treatment of cancer. The company's monoclonal antibody drug candidates and diagnostics products detect and target the tumor without destroying healthy cells, enabling clinicians to treat cancer patients.

Developer of abuse-resistant prescription drugs. The company offers products in the areas of sedative-hypnotic, moderate-to-severe pain, inflammatory pain, opioid-associated side effects, antiemetic, and attention-deficit hyperactivity disorder.

Developer of microbiome modulators intended for metabolic diseases that aim to improve health status by altering microbial populations and their environment in the GI tract. The company's microbiome modulators includes fermentable fiber and polyphenol antioxidants in a patent-pending blendare designed to augment the growth of certain bacterial strains and discourage the growth of others, enabling nurture and nourish beneficial microorganisms in the lower gut.